IMP3 expression in NSCLC brain metastases demonstrates its role as a prognostic factor in non-neuroendocrine phenotypes

Research output: Contribution to journalArticle

Abstract

Brain metastases from NSCLC are associated with a poor prognosis, and local radiotherapy is the most effective therapeutic strategy. The oncofetal protein IMP3 has been studied extensively, and evidence suggests that its expression is related to shorter overall survival and a more aggressive phenotype in solid malignancies. Here, the prognostic role of IMP3 was investigated in a cohort of patients with NSCLC brain metastases in correlation with survival and tumor histotype. A series of 42 NSCLC brain metastases samples was analyzed by tissue microarray and immunohistochemical staining for IMP3. IMP3 expression was associated with shorter overall survival in the whole series and in subgroups of metastases from non-neuroendocrine pulmonary malignancies and adenocarcinoma metastases. These results indicated that IMP3 is a strong prognostic factor in non-neuroendocrine brain metastases and in particular in patients with adenocarcinoma metastases.

Original languageEnglish
Article number2
JournalMedical Oncology
Volume35
Issue number1
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Neoplasm Metastasis
Phenotype
Brain
Survival
Neoplasms
Adenocarcinoma
Radiotherapy
Staining and Labeling
Therapeutics

Keywords

  • Brain metastasis
  • IMP3
  • Microarray
  • NSCLC

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

@article{dfb9cba9a7ff430c83482078e503cdeb,
title = "IMP3 expression in NSCLC brain metastases demonstrates its role as a prognostic factor in non-neuroendocrine phenotypes",
abstract = "Brain metastases from NSCLC are associated with a poor prognosis, and local radiotherapy is the most effective therapeutic strategy. The oncofetal protein IMP3 has been studied extensively, and evidence suggests that its expression is related to shorter overall survival and a more aggressive phenotype in solid malignancies. Here, the prognostic role of IMP3 was investigated in a cohort of patients with NSCLC brain metastases in correlation with survival and tumor histotype. A series of 42 NSCLC brain metastases samples was analyzed by tissue microarray and immunohistochemical staining for IMP3. IMP3 expression was associated with shorter overall survival in the whole series and in subgroups of metastases from non-neuroendocrine pulmonary malignancies and adenocarcinoma metastases. These results indicated that IMP3 is a strong prognostic factor in non-neuroendocrine brain metastases and in particular in patients with adenocarcinoma metastases.",
keywords = "Brain metastasis, IMP3, Microarray, NSCLC",
author = "{Del Gobbo}, Alessandro and Annamaria Morotti and Colombo, {Anna Eleonora} and Valentina Vaira and Giulia Ercoli and Chiara Pesenti and Eleonora Bonaparte and Elena Guerini-Rocco and {Di Cristofori}, Andrea and Marco Locatelli and Alessandro Palleschi and Stefano Ferrero",
year = "2018",
month = "1",
day = "1",
doi = "10.1007/s12032-017-1062-7",
language = "English",
volume = "35",
journal = "Medical Oncology",
issn = "1357-0560",
publisher = "Humana Press Inc.",
number = "1",

}

TY - JOUR

T1 - IMP3 expression in NSCLC brain metastases demonstrates its role as a prognostic factor in non-neuroendocrine phenotypes

AU - Del Gobbo, Alessandro

AU - Morotti, Annamaria

AU - Colombo, Anna Eleonora

AU - Vaira, Valentina

AU - Ercoli, Giulia

AU - Pesenti, Chiara

AU - Bonaparte, Eleonora

AU - Guerini-Rocco, Elena

AU - Di Cristofori, Andrea

AU - Locatelli, Marco

AU - Palleschi, Alessandro

AU - Ferrero, Stefano

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Brain metastases from NSCLC are associated with a poor prognosis, and local radiotherapy is the most effective therapeutic strategy. The oncofetal protein IMP3 has been studied extensively, and evidence suggests that its expression is related to shorter overall survival and a more aggressive phenotype in solid malignancies. Here, the prognostic role of IMP3 was investigated in a cohort of patients with NSCLC brain metastases in correlation with survival and tumor histotype. A series of 42 NSCLC brain metastases samples was analyzed by tissue microarray and immunohistochemical staining for IMP3. IMP3 expression was associated with shorter overall survival in the whole series and in subgroups of metastases from non-neuroendocrine pulmonary malignancies and adenocarcinoma metastases. These results indicated that IMP3 is a strong prognostic factor in non-neuroendocrine brain metastases and in particular in patients with adenocarcinoma metastases.

AB - Brain metastases from NSCLC are associated with a poor prognosis, and local radiotherapy is the most effective therapeutic strategy. The oncofetal protein IMP3 has been studied extensively, and evidence suggests that its expression is related to shorter overall survival and a more aggressive phenotype in solid malignancies. Here, the prognostic role of IMP3 was investigated in a cohort of patients with NSCLC brain metastases in correlation with survival and tumor histotype. A series of 42 NSCLC brain metastases samples was analyzed by tissue microarray and immunohistochemical staining for IMP3. IMP3 expression was associated with shorter overall survival in the whole series and in subgroups of metastases from non-neuroendocrine pulmonary malignancies and adenocarcinoma metastases. These results indicated that IMP3 is a strong prognostic factor in non-neuroendocrine brain metastases and in particular in patients with adenocarcinoma metastases.

KW - Brain metastasis

KW - IMP3

KW - Microarray

KW - NSCLC

UR - http://www.scopus.com/inward/record.url?scp=85037624218&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85037624218&partnerID=8YFLogxK

U2 - 10.1007/s12032-017-1062-7

DO - 10.1007/s12032-017-1062-7

M3 - Article

VL - 35

JO - Medical Oncology

JF - Medical Oncology

SN - 1357-0560

IS - 1

M1 - 2

ER -